サンプル依頼リスト カート
  • English
デフォルト表紙
市場調査レポート
商品コード
1788375

トゥレット症候群治療の世界市場

Tourette Syndrome Treatment

出版日
ページ情報
英文 186 Pages
納期
即日から翌営業日
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=148.66円
トゥレット症候群治療の世界市場
出版日: 2025年08月12日
発行: Global Industry Analysts, Inc.
ページ情報: 英文 186 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

トゥレット症候群治療の世界市場は2030年までに31億米ドルに達する

2024年に23億米ドルと推定されるトゥレット症候群治療の世界市場は、分析期間2024-2030年にCAGR 5.1%で成長し、2030年には31億米ドルに達すると予測されます。本レポートで分析したセグメントの1つである抗精神病薬は、CAGR 4.1%を記録し、分析期間終了時には20億米ドルに達すると予測されます。非抗精神病薬セグメントの成長率は、分析期間中CAGR 7.0%と推定されます。

米国市場は推定6億2,600万米ドル、中国はCAGR 7.9％で成長予測

米国のトゥレット症候群治療市場は、2024年に6億2,600万米ドルと推定されます。世界第2位の経済大国である中国は、分析期間2024-2030年のCAGRを7.9%として、2030年までに6億990万米ドルの市場規模に達すると予測されています。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ2.5％と5.0％と予測されています。欧州では、ドイツがCAGR 3.3%で成長すると予測されています。

トゥレット症候群治療市場の動向と促進要因のまとめ

トゥレット症候群治療は個別化医療とニューロモジュレーションでどのように進歩しているか？

トゥレット症候群（TS）は、反復的で不随意なチックや発声を特徴とする神経疾患で、しばしば小児期に発症します。正確な原因は不明であるが、調査により遺伝的、神経学的、環境的要因が複合的に関与していることが示されています。歴史的に、治療の選択肢は行動療法とドーパミン拮抗薬やαアドレナリン作動薬などの薬理学的介入に限られてきました。しかし、個別化医療、神経調節技術、遺伝子治療が重視されるようになり、治療法は大きく変わりつつあります。脳深部刺激療法（DBS）や経頭蓋磁気刺激療法（TMS）は、重症例に対する有望な非侵襲的ソリューションとして台頭してきており、従来の薬物療法に伴う副作用を伴わずに症状コントロールを改善します。しかし、診断の遅れ、症状の重症度のばらつき、治療へのアクセスの制限といった課題は依然として残っています。神経精神医学の研究が進むにつれ、標的治療やデジタル治療における技術革新は、トゥレット症候群治療の未来をどのように再定義していくのだろうか。

どのような技術革新がトゥレット症候群治療を前進させているのか？

TS治療における最近のブレークスルーは、精密な神経調節、AI主導の診断ツール、薬理ゲノミクスに焦点を当てています。もともとパーキンソン病のために開発されたDBSは、現在TSのために研究されており、異常な神経回路を調整するのに役立っています。AIベースの認知行動療法（CBT）アプリは遠隔チック管理を可能にし、治療をより身近なものにしています。遺伝学的調査により、TSの潜在的なバイオマーカーが明らかになりつつあり、個々の患者に合わせた標的療法への道が開かれつつあります。さらに、リアルタイムのバイオフィードバックメカニズムを備えたウェアラブルデバイスがデジタル治療薬として台頭しており、ニューロフィードバックや習慣逆転トレーニングを通じてチック症の管理を支援しています。

なぜトゥレット症候群治療の需要が高まっているのか？

神経発達障害の有病率の増加、TSに対する意識の高まり、非侵襲的神経調節の進歩が、革新的な治療に対する需要を促進しています。親や介護者は、副作用への懸念から薬物療法以外の代替療法を求めています。さらに、遠隔医療やデジタル治療法の採用が増加していることで、行動介入へのアクセスが拡大し、市場の成長をさらに後押ししています。

トゥレット症候群治療市場の成長を促進する要因は？

神経刺激療法の進歩、遺伝学的・神経生物学的メカニズムに関する調査の増加、非薬物療法に対する需要の高まり、デジタルヘルスソリューションの拡大などにより、市場は拡大しています。トゥレット症候群の理解が進むにつれて、将来の治療は個別化された技術主導の介入に焦点が当てられ、患者の転帰とQOLが向上する可能性が高いです。

セグメント

治療タイプ（抗精神病薬、非抗精神病薬）

調査対象企業の例

  • AbbVie Inc.
  • Abide Therapeutics
  • Acorda Therapeutics
  • Anika Therapeutics Inc.
  • Apotex Inc.
  • Arbor Pharmaceuticals
  • AstraZeneca PLC
  • Bausch Health Companies Inc.
  • Bayer AG
  • Biogen Inc.
  • Boehringer Ingelheim International GmbH
  • Bristol-Myers Squibb
  • Catalyst Pharmaceuticals, Inc.
  • Eli Lilly and Company
  • Emalex Biosciences, Inc.
  • F. Hoffmann-La Roche AG
  • H. Lundbeck A/S
  • Janssen Pharmaceuticals, Inc.
  • Jazz Pharmaceuticals plc
  • Kyowa Kirin Co., Ltd.
  • Mitsubishi Tanabe Pharma Corporation
  • Neurocrine Biosciences, Inc.

AI統合

当社は、有効な専門家コンテンツとAIツールにより、市場情報と競合情報を変革しています。

Global Industry Analystsは、LLMや業界固有のSLMを照会する一般的な規範に従う代わりに、ビデオ記録、ブログ、検索エンジン調査、膨大な量の企業、製品/サービス、市場データなど、世界中の専門家から収集したコンテンツのリポジトリを構築しました。

関税影響係数

Global Industry Analystsは、本社の国、製造拠点、輸出入（完成品とOEM）に基づく企業の競争力の変化を予測しています。この複雑で多面的な市場力学は、売上原価（COGS）の増加、収益性の低下、サプライチェーンの再構築など、ミクロおよびマクロの市場力学の中でも特に競合他社に影響を与える見込みです。

目次

第1章 調査手法

第2章 エグゼクティブサマリー

  • 市場概要
  • 主要企業
  • 市場動向と促進要因
  • 世界市場の見通し

第3章 市場分析

  • 米国
  • カナダ
  • 日本
  • 中国
  • 欧州
  • フランス
  • ドイツ
  • イタリア
  • 英国
  • スペイン
  • ロシア
  • その他欧州
  • アジア太平洋
  • オーストラリア
  • インド
  • 韓国
  • その他アジア太平洋地域
  • ラテンアメリカ
  • アルゼンチン
  • ブラジル
  • メキシコ
  • その他ラテンアメリカ
  • 中東
  • イラン
  • イスラエル
  • サウジアラビア
  • アラブ首長国連邦
  • その他中東
  • アフリカ

第4章 競合

目次
Product Code: MCP33165

Global Tourette Syndrome Treatment Market to Reach US$3.1 Billion by 2030

The global market for Tourette Syndrome Treatment estimated at US$2.3 Billion in the year 2024, is expected to reach US$3.1 Billion by 2030, growing at a CAGR of 5.1% over the analysis period 2024-2030. Antipsychotics, one of the segments analyzed in the report, is expected to record a 4.1% CAGR and reach US$2.0 Billion by the end of the analysis period. Growth in the Non-Antipsychotics segment is estimated at 7.0% CAGR over the analysis period.

The U.S. Market is Estimated at US$626.0 Million While China is Forecast to Grow at 7.9% CAGR

The Tourette Syndrome Treatment market in the U.S. is estimated at US$626.0 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$609.9 Million by the year 2030 trailing a CAGR of 7.9% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 2.5% and 5.0% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 3.3% CAGR.

Tourette Syndrome Treatment Market Trends & Drivers Summarized

How Is Tourette Syndrome Treatment Advancing with Personalized Medicine and Neuromodulation?

Tourette Syndrome (TS) is a neurological disorder characterized by repetitive, involuntary tics and vocalizations, often appearing in childhood. While the exact cause remains unclear, research indicates a combination of genetic, neurological, and environmental factors. Historically, treatment options have been limited to behavioral therapy and pharmacological interventions, such as dopamine antagonists and alpha-adrenergic agonists. However, the growing emphasis on personalized medicine, neuromodulation techniques, and gene therapy is transforming the treatment landscape. Deep brain stimulation (DBS) and transcranial magnetic stimulation (TMS) are emerging as promising non-invasive solutions for severe cases, offering improved symptom control without the side effects associated with traditional medications. However, challenges such as delayed diagnosis, variability in symptom severity, and limited treatment accessibility persist. As neuropsychiatric research advances, how will innovations in targeted therapies and digital therapeutics redefine the future of Tourette Syndrome treatment?

What Technological Innovations Are Advancing Tourette Syndrome Treatment?

Recent breakthroughs in TS treatment focus on precision neuromodulation, AI-driven diagnostic tools, and pharmacogenomics. DBS, originally developed for Parkinson’s disease, is now being explored for TS, helping to regulate abnormal neural circuits. AI-based cognitive behavioral therapy (CBT) apps are enabling remote tic management, making treatment more accessible. Genetic research is uncovering potential biomarkers for TS, paving the way for targeted therapies tailored to individual patients. Additionally, wearable devices with real-time biofeedback mechanisms are emerging as digital therapeutics, helping individuals manage tics through neurofeedback and habit-reversal training.

Why Is the Demand for Tourette Syndrome Treatment Increasing?

The increasing prevalence of neurodevelopmental disorders, growing awareness of TS, and advancements in non-invasive neuromodulation are driving demand for innovative treatments. Parents and caregivers are seeking alternative therapies beyond medication due to concerns over side effects. Additionally, the rising adoption of telemedicine and digital therapeutics is expanding access to behavioral interventions, further fueling market growth.

What Factors Are Driving the Growth of the Tourette Syndrome Treatment Market?

The market is expanding due to advancements in neurostimulation therapies, increasing research into genetic and neurobiological mechanisms, growing demand for non-pharmacological treatments, and expanding digital health solutions. As the understanding of Tourette Syndrome improves, future treatments will likely focus on personalized and technology-driven interventions, enhancing patient outcomes and quality of life.

SCOPE OF STUDY:

The report analyzes the Tourette Syndrome Treatment market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Treatment Type (Antipsychotics, Non-Antipsychotics)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 48 Featured) -

  • AbbVie Inc.
  • Abide Therapeutics
  • Acorda Therapeutics
  • Anika Therapeutics Inc.
  • Apotex Inc.
  • Arbor Pharmaceuticals
  • AstraZeneca PLC
  • Bausch Health Companies Inc.
  • Bayer AG
  • Biogen Inc.
  • Boehringer Ingelheim International GmbH
  • Bristol-Myers Squibb
  • Catalyst Pharmaceuticals, Inc.
  • Eli Lilly and Company
  • Emalex Biosciences, Inc.
  • F. Hoffmann-La Roche AG
  • H. Lundbeck A/S
  • Janssen Pharmaceuticals, Inc.
  • Jazz Pharmaceuticals plc
  • Kyowa Kirin Co., Ltd.
  • Mitsubishi Tanabe Pharma Corporation
  • Neurocrine Biosciences, Inc.

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • Tariff Impact on Global Supply Chain Patterns
    • Tourette Syndrome Treatment - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Increasing Diagnosis Rates and Awareness Campaigns Drive Demand for Therapeutic Options
    • Expansion of Behavioral Therapy Access Enhances Non-Pharmacologic Treatment Demand
    • Clinical Development of Dopamine Modulators and VMAT2 Inhibitors Advances Drug Pipeline
    • Rise in Pediatric Neuropsychiatry Services Strengthens Early Intervention Initiatives
    • Growing Research Into Comorbidity Management (ADHD, OCD) Expands Treatment Scope
    • Use of Digital CBT Tools and Virtual Consults Supports Decentralized Behavioral Therapies
    • Development of Long-Acting Injectable Formulations Improves Adherence and Quality of Life
    • Clinical Trials Targeting Genetic and Neurobiological Mechanisms Enhance Innovation
    • Regulatory Fast Track and Orphan Drug Status Incentivize R&D Investment
    • Integration of Multidisciplinary Care Models Improves Treatment Coordination
    • Advocacy Group Engagement and Support Networks Improve Patient Retention
    • Emerging Interest in Neuromodulation and DBS for Refractory Cases Expands Research Frontiers
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Tourette Syndrome Treatment Market Analysis of Annual Sales in US$ Million for Years 2015 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Tourette Syndrome Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Tourette Syndrome Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 4: World 15-Year Perspective for Tourette Syndrome Treatment by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2015, 2025 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Antipsychotics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Antipsychotics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 7: World 15-Year Perspective for Antipsychotics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Non-Antipsychotics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Non-Antipsychotics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 10: World 15-Year Perspective for Non-Antipsychotics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Tourette Syndrome Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 11: USA Recent Past, Current & Future Analysis for Tourette Syndrome Treatment by Treatment Type - Antipsychotics and Non-Antipsychotics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 12: USA Historic Review for Tourette Syndrome Treatment by Treatment Type - Antipsychotics and Non-Antipsychotics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 13: USA 15-Year Perspective for Tourette Syndrome Treatment by Treatment Type - Percentage Breakdown of Value Sales for Antipsychotics and Non-Antipsychotics for the Years 2015, 2025 & 2030
  • CANADA
    • TABLE 14: Canada Recent Past, Current & Future Analysis for Tourette Syndrome Treatment by Treatment Type - Antipsychotics and Non-Antipsychotics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 15: Canada Historic Review for Tourette Syndrome Treatment by Treatment Type - Antipsychotics and Non-Antipsychotics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 16: Canada 15-Year Perspective for Tourette Syndrome Treatment by Treatment Type - Percentage Breakdown of Value Sales for Antipsychotics and Non-Antipsychotics for the Years 2015, 2025 & 2030
  • JAPAN
    • Tourette Syndrome Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 17: Japan Recent Past, Current & Future Analysis for Tourette Syndrome Treatment by Treatment Type - Antipsychotics and Non-Antipsychotics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 18: Japan Historic Review for Tourette Syndrome Treatment by Treatment Type - Antipsychotics and Non-Antipsychotics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 19: Japan 15-Year Perspective for Tourette Syndrome Treatment by Treatment Type - Percentage Breakdown of Value Sales for Antipsychotics and Non-Antipsychotics for the Years 2015, 2025 & 2030
  • CHINA
    • Tourette Syndrome Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 20: China Recent Past, Current & Future Analysis for Tourette Syndrome Treatment by Treatment Type - Antipsychotics and Non-Antipsychotics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 21: China Historic Review for Tourette Syndrome Treatment by Treatment Type - Antipsychotics and Non-Antipsychotics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 22: China 15-Year Perspective for Tourette Syndrome Treatment by Treatment Type - Percentage Breakdown of Value Sales for Antipsychotics and Non-Antipsychotics for the Years 2015, 2025 & 2030
  • EUROPE
    • Tourette Syndrome Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 23: Europe Recent Past, Current & Future Analysis for Tourette Syndrome Treatment by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 24: Europe Historic Review for Tourette Syndrome Treatment by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 25: Europe 15-Year Perspective for Tourette Syndrome Treatment by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2015, 2025 & 2030
    • TABLE 26: Europe Recent Past, Current & Future Analysis for Tourette Syndrome Treatment by Treatment Type - Antipsychotics and Non-Antipsychotics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 27: Europe Historic Review for Tourette Syndrome Treatment by Treatment Type - Antipsychotics and Non-Antipsychotics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 28: Europe 15-Year Perspective for Tourette Syndrome Treatment by Treatment Type - Percentage Breakdown of Value Sales for Antipsychotics and Non-Antipsychotics for the Years 2015, 2025 & 2030
  • FRANCE
    • Tourette Syndrome Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 29: France Recent Past, Current & Future Analysis for Tourette Syndrome Treatment by Treatment Type - Antipsychotics and Non-Antipsychotics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 30: France Historic Review for Tourette Syndrome Treatment by Treatment Type - Antipsychotics and Non-Antipsychotics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 31: France 15-Year Perspective for Tourette Syndrome Treatment by Treatment Type - Percentage Breakdown of Value Sales for Antipsychotics and Non-Antipsychotics for the Years 2015, 2025 & 2030
  • GERMANY
    • Tourette Syndrome Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 32: Germany Recent Past, Current & Future Analysis for Tourette Syndrome Treatment by Treatment Type - Antipsychotics and Non-Antipsychotics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 33: Germany Historic Review for Tourette Syndrome Treatment by Treatment Type - Antipsychotics and Non-Antipsychotics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 34: Germany 15-Year Perspective for Tourette Syndrome Treatment by Treatment Type - Percentage Breakdown of Value Sales for Antipsychotics and Non-Antipsychotics for the Years 2015, 2025 & 2030
  • ITALY
    • TABLE 35: Italy Recent Past, Current & Future Analysis for Tourette Syndrome Treatment by Treatment Type - Antipsychotics and Non-Antipsychotics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 36: Italy Historic Review for Tourette Syndrome Treatment by Treatment Type - Antipsychotics and Non-Antipsychotics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 37: Italy 15-Year Perspective for Tourette Syndrome Treatment by Treatment Type - Percentage Breakdown of Value Sales for Antipsychotics and Non-Antipsychotics for the Years 2015, 2025 & 2030
  • UNITED KINGDOM
    • Tourette Syndrome Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 38: UK Recent Past, Current & Future Analysis for Tourette Syndrome Treatment by Treatment Type - Antipsychotics and Non-Antipsychotics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 39: UK Historic Review for Tourette Syndrome Treatment by Treatment Type - Antipsychotics and Non-Antipsychotics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 40: UK 15-Year Perspective for Tourette Syndrome Treatment by Treatment Type - Percentage Breakdown of Value Sales for Antipsychotics and Non-Antipsychotics for the Years 2015, 2025 & 2030
  • SPAIN
    • TABLE 41: Spain Recent Past, Current & Future Analysis for Tourette Syndrome Treatment by Treatment Type - Antipsychotics and Non-Antipsychotics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 42: Spain Historic Review for Tourette Syndrome Treatment by Treatment Type - Antipsychotics and Non-Antipsychotics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 43: Spain 15-Year Perspective for Tourette Syndrome Treatment by Treatment Type - Percentage Breakdown of Value Sales for Antipsychotics and Non-Antipsychotics for the Years 2015, 2025 & 2030
  • RUSSIA
    • TABLE 44: Russia Recent Past, Current & Future Analysis for Tourette Syndrome Treatment by Treatment Type - Antipsychotics and Non-Antipsychotics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 45: Russia Historic Review for Tourette Syndrome Treatment by Treatment Type - Antipsychotics and Non-Antipsychotics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 46: Russia 15-Year Perspective for Tourette Syndrome Treatment by Treatment Type - Percentage Breakdown of Value Sales for Antipsychotics and Non-Antipsychotics for the Years 2015, 2025 & 2030
  • REST OF EUROPE
    • TABLE 47: Rest of Europe Recent Past, Current & Future Analysis for Tourette Syndrome Treatment by Treatment Type - Antipsychotics and Non-Antipsychotics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 48: Rest of Europe Historic Review for Tourette Syndrome Treatment by Treatment Type - Antipsychotics and Non-Antipsychotics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 49: Rest of Europe 15-Year Perspective for Tourette Syndrome Treatment by Treatment Type - Percentage Breakdown of Value Sales for Antipsychotics and Non-Antipsychotics for the Years 2015, 2025 & 2030
  • ASIA-PACIFIC
    • Tourette Syndrome Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 50: Asia-Pacific Recent Past, Current & Future Analysis for Tourette Syndrome Treatment by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 51: Asia-Pacific Historic Review for Tourette Syndrome Treatment by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 52: Asia-Pacific 15-Year Perspective for Tourette Syndrome Treatment by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2015, 2025 & 2030
    • TABLE 53: Asia-Pacific Recent Past, Current & Future Analysis for Tourette Syndrome Treatment by Treatment Type - Antipsychotics and Non-Antipsychotics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 54: Asia-Pacific Historic Review for Tourette Syndrome Treatment by Treatment Type - Antipsychotics and Non-Antipsychotics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 55: Asia-Pacific 15-Year Perspective for Tourette Syndrome Treatment by Treatment Type - Percentage Breakdown of Value Sales for Antipsychotics and Non-Antipsychotics for the Years 2015, 2025 & 2030
  • AUSTRALIA
    • Tourette Syndrome Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
    • TABLE 56: Australia Recent Past, Current & Future Analysis for Tourette Syndrome Treatment by Treatment Type - Antipsychotics and Non-Antipsychotics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 57: Australia Historic Review for Tourette Syndrome Treatment by Treatment Type - Antipsychotics and Non-Antipsychotics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 58: Australia 15-Year Perspective for Tourette Syndrome Treatment by Treatment Type - Percentage Breakdown of Value Sales for Antipsychotics and Non-Antipsychotics for the Years 2015, 2025 & 2030
  • INDIA
    • Tourette Syndrome Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
    • TABLE 59: India Recent Past, Current & Future Analysis for Tourette Syndrome Treatment by Treatment Type - Antipsychotics and Non-Antipsychotics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 60: India Historic Review for Tourette Syndrome Treatment by Treatment Type - Antipsychotics and Non-Antipsychotics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 61: India 15-Year Perspective for Tourette Syndrome Treatment by Treatment Type - Percentage Breakdown of Value Sales for Antipsychotics and Non-Antipsychotics for the Years 2015, 2025 & 2030
  • SOUTH KOREA
    • TABLE 62: South Korea Recent Past, Current & Future Analysis for Tourette Syndrome Treatment by Treatment Type - Antipsychotics and Non-Antipsychotics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 63: South Korea Historic Review for Tourette Syndrome Treatment by Treatment Type - Antipsychotics and Non-Antipsychotics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 64: South Korea 15-Year Perspective for Tourette Syndrome Treatment by Treatment Type - Percentage Breakdown of Value Sales for Antipsychotics and Non-Antipsychotics for the Years 2015, 2025 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 65: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Tourette Syndrome Treatment by Treatment Type - Antipsychotics and Non-Antipsychotics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 66: Rest of Asia-Pacific Historic Review for Tourette Syndrome Treatment by Treatment Type - Antipsychotics and Non-Antipsychotics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 67: Rest of Asia-Pacific 15-Year Perspective for Tourette Syndrome Treatment by Treatment Type - Percentage Breakdown of Value Sales for Antipsychotics and Non-Antipsychotics for the Years 2015, 2025 & 2030
  • LATIN AMERICA
    • Tourette Syndrome Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
    • TABLE 68: Latin America Recent Past, Current & Future Analysis for Tourette Syndrome Treatment by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 69: Latin America Historic Review for Tourette Syndrome Treatment by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 70: Latin America 15-Year Perspective for Tourette Syndrome Treatment by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2015, 2025 & 2030
    • TABLE 71: Latin America Recent Past, Current & Future Analysis for Tourette Syndrome Treatment by Treatment Type - Antipsychotics and Non-Antipsychotics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 72: Latin America Historic Review for Tourette Syndrome Treatment by Treatment Type - Antipsychotics and Non-Antipsychotics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 73: Latin America 15-Year Perspective for Tourette Syndrome Treatment by Treatment Type - Percentage Breakdown of Value Sales for Antipsychotics and Non-Antipsychotics for the Years 2015, 2025 & 2030
  • ARGENTINA
    • TABLE 74: Argentina Recent Past, Current & Future Analysis for Tourette Syndrome Treatment by Treatment Type - Antipsychotics and Non-Antipsychotics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 75: Argentina Historic Review for Tourette Syndrome Treatment by Treatment Type - Antipsychotics and Non-Antipsychotics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 76: Argentina 15-Year Perspective for Tourette Syndrome Treatment by Treatment Type - Percentage Breakdown of Value Sales for Antipsychotics and Non-Antipsychotics for the Years 2015, 2025 & 2030
  • BRAZIL
    • TABLE 77: Brazil Recent Past, Current & Future Analysis for Tourette Syndrome Treatment by Treatment Type - Antipsychotics and Non-Antipsychotics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 78: Brazil Historic Review for Tourette Syndrome Treatment by Treatment Type - Antipsychotics and Non-Antipsychotics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 79: Brazil 15-Year Perspective for Tourette Syndrome Treatment by Treatment Type - Percentage Breakdown of Value Sales for Antipsychotics and Non-Antipsychotics for the Years 2015, 2025 & 2030
  • MEXICO
    • TABLE 80: Mexico Recent Past, Current & Future Analysis for Tourette Syndrome Treatment by Treatment Type - Antipsychotics and Non-Antipsychotics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 81: Mexico Historic Review for Tourette Syndrome Treatment by Treatment Type - Antipsychotics and Non-Antipsychotics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 82: Mexico 15-Year Perspective for Tourette Syndrome Treatment by Treatment Type - Percentage Breakdown of Value Sales for Antipsychotics and Non-Antipsychotics for the Years 2015, 2025 & 2030
  • REST OF LATIN AMERICA
    • TABLE 83: Rest of Latin America Recent Past, Current & Future Analysis for Tourette Syndrome Treatment by Treatment Type - Antipsychotics and Non-Antipsychotics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 84: Rest of Latin America Historic Review for Tourette Syndrome Treatment by Treatment Type - Antipsychotics and Non-Antipsychotics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 85: Rest of Latin America 15-Year Perspective for Tourette Syndrome Treatment by Treatment Type - Percentage Breakdown of Value Sales for Antipsychotics and Non-Antipsychotics for the Years 2015, 2025 & 2030
  • MIDDLE EAST
    • Tourette Syndrome Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
    • TABLE 86: Middle East Recent Past, Current & Future Analysis for Tourette Syndrome Treatment by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 87: Middle East Historic Review for Tourette Syndrome Treatment by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 88: Middle East 15-Year Perspective for Tourette Syndrome Treatment by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2015, 2025 & 2030
    • TABLE 89: Middle East Recent Past, Current & Future Analysis for Tourette Syndrome Treatment by Treatment Type - Antipsychotics and Non-Antipsychotics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 90: Middle East Historic Review for Tourette Syndrome Treatment by Treatment Type - Antipsychotics and Non-Antipsychotics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 91: Middle East 15-Year Perspective for Tourette Syndrome Treatment by Treatment Type - Percentage Breakdown of Value Sales for Antipsychotics and Non-Antipsychotics for the Years 2015, 2025 & 2030
  • IRAN
    • TABLE 92: Iran Recent Past, Current & Future Analysis for Tourette Syndrome Treatment by Treatment Type - Antipsychotics and Non-Antipsychotics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 93: Iran Historic Review for Tourette Syndrome Treatment by Treatment Type - Antipsychotics and Non-Antipsychotics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 94: Iran 15-Year Perspective for Tourette Syndrome Treatment by Treatment Type - Percentage Breakdown of Value Sales for Antipsychotics and Non-Antipsychotics for the Years 2015, 2025 & 2030
  • ISRAEL
    • TABLE 95: Israel Recent Past, Current & Future Analysis for Tourette Syndrome Treatment by Treatment Type - Antipsychotics and Non-Antipsychotics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 96: Israel Historic Review for Tourette Syndrome Treatment by Treatment Type - Antipsychotics and Non-Antipsychotics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 97: Israel 15-Year Perspective for Tourette Syndrome Treatment by Treatment Type - Percentage Breakdown of Value Sales for Antipsychotics and Non-Antipsychotics for the Years 2015, 2025 & 2030
  • SAUDI ARABIA
    • TABLE 98: Saudi Arabia Recent Past, Current & Future Analysis for Tourette Syndrome Treatment by Treatment Type - Antipsychotics and Non-Antipsychotics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 99: Saudi Arabia Historic Review for Tourette Syndrome Treatment by Treatment Type - Antipsychotics and Non-Antipsychotics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 100: Saudi Arabia 15-Year Perspective for Tourette Syndrome Treatment by Treatment Type - Percentage Breakdown of Value Sales for Antipsychotics and Non-Antipsychotics for the Years 2015, 2025 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 101: UAE Recent Past, Current & Future Analysis for Tourette Syndrome Treatment by Treatment Type - Antipsychotics and Non-Antipsychotics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 102: UAE Historic Review for Tourette Syndrome Treatment by Treatment Type - Antipsychotics and Non-Antipsychotics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 103: UAE 15-Year Perspective for Tourette Syndrome Treatment by Treatment Type - Percentage Breakdown of Value Sales for Antipsychotics and Non-Antipsychotics for the Years 2015, 2025 & 2030
  • REST OF MIDDLE EAST
    • TABLE 104: Rest of Middle East Recent Past, Current & Future Analysis for Tourette Syndrome Treatment by Treatment Type - Antipsychotics and Non-Antipsychotics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 105: Rest of Middle East Historic Review for Tourette Syndrome Treatment by Treatment Type - Antipsychotics and Non-Antipsychotics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 106: Rest of Middle East 15-Year Perspective for Tourette Syndrome Treatment by Treatment Type - Percentage Breakdown of Value Sales for Antipsychotics and Non-Antipsychotics for the Years 2015, 2025 & 2030
  • AFRICA
    • Tourette Syndrome Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
    • TABLE 107: Africa Recent Past, Current & Future Analysis for Tourette Syndrome Treatment by Treatment Type - Antipsychotics and Non-Antipsychotics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 108: Africa Historic Review for Tourette Syndrome Treatment by Treatment Type - Antipsychotics and Non-Antipsychotics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 109: Africa 15-Year Perspective for Tourette Syndrome Treatment by Treatment Type - Percentage Breakdown of Value Sales for Antipsychotics and Non-Antipsychotics for the Years 2015, 2025 & 2030

IV. COMPETITION